Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#3076 Endometrial Small Cell Neuroendocrine Carcinoma: Case Report and Literature Review

Introduction: Endometrial small-cell neuroendocrine carcinoma (ESCNEC) is extremely rare. It is characterized by early regional and systemic spread leading to rapid development of lymph nodes, pelvic and extrapelvic metastasis and compromising the outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aris H, Ghomari S,

Keywords: endometrial small cell neuroendocrine carcinoma, surgery, adjuvant chemotherapy, brachytherapy,

#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report

Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,

Keywords: ACC, chemotherapy, mitotane, local therapy,

#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo L

Authors: Mastrangelo L, Cipressi C, Masetti M, Zanello M, Romboli A,

Keywords: nomogram, pancreatic neuroendocrine tumor, recurrence,

#2899 Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China

Introduction: Surgery was the preferred treatment in patients with resectable pancreatic neuroendocrine tumor (pNET), but recurrent lesion relapsed frequently within a short time. It was controversial whether patients with pNET need adjuvant therapy after surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shi X

Authors: Shi X, Xu X, Zhang Y, Gao S, Li B,

Keywords: somatostatin analogue, adjuvant therapy, pancreatic neuroendocrine tumor,